Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CASI Pharmaceuticals, Inc. (CASIF)
USD0.13
-0.02 (-13.63%)
CN PNK Healthcare Biotechnology
Address
1701-1702, China Central Office Tower 1 100025
Beijing, CN
Beijing, CN
CEO
Wei-Wu He
Website
casipharmaceuticals.com
IPO
1996-06-12
CIK 1962738 ISIN KYG1933S1012
Also trades on
NASDAQ Capital Market · CASI (USD)
Other OTC · CASIF (USD)
Description
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The company's offerings include EVOMELA, an intravenous formulation of melphalan, which serves as a conditioning treatment before stem cell transplantation and as palliative care for patients with multiple myeloma. Its hematology/oncology pipeline is robust, featuring CNCT19, an investigative autologous CD19 CAR-T product; BI-1206, a novel anti-FcγRIIB antibody designed for treating solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, an innovative VCP/p97 inhibitor targeting valosin-containing protein (VCP)/p97 pathways crucial for protein homeostasis, DNA damage response, and cellular stress in various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with diverse indications, including its use as a conditioning regimen prior to certain allogeneic hematopoietic stem cell transplants. CASI Pharmaceuticals maintains licensing agreements with entities such as Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., primarily for the development and commercialization of its commercial product, EVOMELA. The company was founded in 1991 and is headquartered in Beijing, People's Republic of China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.13
-0.02 (-13.63%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
14.7K
Beta
1.49
Float Shares
9.28M
Free Float %
45.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.33% | -13.33% | -13.33% | -43.26% | -87.25% | -84.71% | -93.12% | -95.32% | -99.19% | -98.96% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
0.13
Low
6.00
+4,700.0%
Consensus
6.00
+4,700.0%
Median
6.00
+4,700.0%
High
6.00
+4,700.0%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
9.00
+7,100.0%
|
Quality scores
Altman Z-Score
-48.04
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-27.4% Q4'25: -45.9% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%-1.2% Q4'25: +32.3% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-115.6% Q4'25: +0.0% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%-206.9% Q4'25: -161.4% (vs Q4'24)
-
ROIC Biotechnology: -16.1%— Q4'25: +302.2% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+20.9% Q4'25: +32.7% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.66× Q4'25: -0.59× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
28.54M
est: 19.80M (+44.2%)
|
20.71M
est: 13.49M (+53.5%)
|
45.48M
45.48M – 45.48M
+237.1% YoY
|
89.46M
89.46M – 89.46M
+96.7% YoY
|
108.07M
108.07M – 108.07M
+20.8% YoY
|
11.18M
11.18M – 11.18M
-89.7% YoY
|
| EBITDA |
-34.87M
est: -17.68M (-97.2%)
|
-41.59M
est: -12.05M (-245.2%)
|
-40.62M
-40.62M – -40.62M
-237.1% YoY
|
-79.91M
-79.91M – -79.91M
-96.7% YoY
|
-96.53M
-96.53M – -96.53M
-20.8% YoY
|
-9.98M
-9.98M – -9.98M
+89.7% YoY
|
| EBIT |
-37.20M
est: -18.34M (-102.8%)
|
-42.85M
est: -12.50M (-242.8%)
|
-42.14M
-42.14M – -42.14M
-237.1% YoY
|
-82.89M
-82.89M – -82.89M
-96.7% YoY
|
-100.13M
-100.13M – -100.13M
-20.8% YoY
|
-10.35M
-10.35M – -10.35M
+89.7% YoY
|
| Net Income |
-39.26M
est: -39.27M (+0.0%)
|
-48.06M
est: -39.58M (-21.4%)
|
-21.63M
-21.63M – -21.63M
+45.3% YoY
|
-21.32M
-21.32M – -21.32M
+1.4% YoY
|
-21.02M
-21.02M – -21.02M
+1.4% YoY
|
-14.88M
-14.88M – -14.88M
+29.2% YoY
|
| SGA |
41.44M
est: 26.33M (+57.4%)
|
46.61M
est: 17.94M (+159.8%)
|
60.50M
60.50M – 60.50M
+237.1% YoY
|
119.01M
119.01M – 119.01M
+96.7% YoY
|
143.76M
143.76M – 143.76M
+20.8% YoY
|
14.87M
14.87M – 14.87M
-89.7% YoY
|
| EPS |
-2.56
est: -2.56 (+0.0%)
|
-2.59
est: -2.58 (-0.4%)
|
-1.41
-1.41 – -1.41
+45.3% YoY
|
-1.39
-1.39 – -1.39
+1.4% YoY
|
-1.37
-1.37 – -1.37
+1.4% YoY
|
-0.97
-0.97 – -0.97
+29.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.48M
OE per share TTM
0.17
Owner's Yield
123.66%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
51.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
7
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2028-06-18 | Wang Chunhua | Officer | — | — | Option (right to buy) | 7,500 | 2.67 | 20.0K | 0 | D | ↗ |
| 2028-06-18 | Qian Kun | Officer | — | — | Option (right to buy) | 3,000 | 2.67 | 8.0K | 0 | D | ↗ |
| 2028-06-18 | Huang Hai | Officer | — | — | Option (right to buy) | 7,500 | 2.67 | 20.0K | 0 | D | ↗ |
| 2027-06-18 | Gao Wei R | Officer | — | — | Option (right to buy) | 5,000 | 2.67 | 13.4K | 0 | D | ↗ |
| 2026-05-21 | He Wei-Wu | Director / 10% Owner | — | — | Convertible Note (right to convert) | 0 | 0.00 | — | 0 | I | ↗ |
| 2026-05-12 | Wang Chunhua | Officer | — | — | Option (right to buy) | 8,333 | 1.93 | 16.1K | 0 | D | ↗ |
| 2026-05-12 | Qian Kun | Officer | — | — | Option (right to buy) | 6,667 | 1.93 | 12.9K | 0 | D | ↗ |
| 2026-03-18 | Zukiwski Alexander A | Officer | — | — | Option (right to buy) | 13,333 | 1.93 | 25.7K | 0 | D | ↗ |
| 2026-03-18 | Zeng Xuebo | Director | — | — | Option (right to buy) | 11,231 | 1.26 | 14.2K | 0 | D | ↗ |
| 2026-03-18 | Wu Alex | Director | — | — | Option (right to buy) | 11,753 | 1.93 | 22.7K | 0 | D | ↗ |
| 2026-03-18 | Wang Chunhua | Officer | — | — | Option (right to buy) | 20,000 | 5.78 | 115.6K | 0 | D | ↗ |
| 2026-03-18 | Qian Kun | Officer | — | — | Option (right to buy) | 5,000 | 5.78 | 28.9K | 0 | D | ↗ |
| 2026-03-18 | Krebs-Pohl Barbara Helene Hannelore | Director | — | — | Option (right to buy) | 10,000 | 2.31 | 23.1K | 0 | D | ↗ |
| 2026-03-18 | Huang Hai | Officer | — | — | Option (right to buy) | 100,000 | 6.61 | 661.0K | 0 | D | ↗ |
| 2026-03-18 | He Wei-Wu | Director / 10% Owner | — | — | Ordinary Share | 0 | 0.00 | — | 1,910,550 | D | ↗ |
| 2026-03-18 | Gao Wei R | Officer | — | — | Option (right to buy) | 4,000 | 1.93 | 7.7K | 0 | D | ↗ |
| 2026-03-18 | Folinsbee Thomas | Director | — | — | Option (right to buy) | 11,231 | 2.67 | 30.0K | 0 | D | ↗ |
| 2022-09-07 | Zukiwski Alexander A | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 3,000 | 15.20 | 45.6K | 3,000 | — | ↗ |
| 2022-09-06 | Huang James | Director | P-Purchase | A | Common Stock | 33,300 | 4.28 | 142.6K | 371,517 | — | ↗ |
| 2022-08-31 | Huang James | Director | P-Purchase | A | Common Stock | 400 | 3.74 | 1.5K | 315,944 | — | ↗ |
| 2022-08-24 | Huang James | Director | P-Purchase | A | Common Stock | 39,527 | 3.75 | 148.2K | 278,748 | — | ↗ |
| 2022-08-19 | Huang James | Director | P-Purchase | A | Common Stock | 40,000 | 3.50 | 140.0K | 234,221 | — | ↗ |
| 2022-06-15 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 50,000 | 3.18 | 159.0K | 644,553 | — | ↗ |
| 2022-06-13 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 36,058 | 2.97 | 107.1K | 592,457 | — | ↗ |
| 2022-05-25 | Zhou Quan | Director | A-Award | A | Stock Option (Right to Buy) | 380,645 | 0.47 | 177.5K | 380,645 | — | ↗ |
| 2022-05-25 | Wu Yue Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 388,387 | 0.00 | — | 388,387 | — | ↗ |
| 2022-05-25 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Option (Right to Buy) | 388,387 | 0.00 | — | 388,387 | — | ↗ |
| 2022-05-25 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Option (Right to Buy) | 345,806 | 0.00 | — | 345,806 | — | ↗ |
| 2022-05-25 | Huang James | Director | A-Award | A | Stock Option (Right to Buy) | 397,419 | 0.00 | — | 397,419 | — | ↗ |
| 2021-12-02 | Zukiwski Alexander A | Officer | A-Award | D | Employee Stock Option (Right to Buy) | 500,000 | 0.87 | 435.0K | 500,000 | — | ↗ |
| 2021-11-18 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 200,000 | 0.98 | 196.0K | 5,558,472 | — | ↗ |
| 2021-11-17 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 200,000 | 0.99 | 198.0K | 5,362,569 | — | ↗ |
| 2021-08-19 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 180,000 | 1.26 | 226.8K | 5,163,994 | — | ↗ |
| 2021-08-18 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 300,000 | 1.29 | 387.0K | 4,983,994 | — | ↗ |
| 2021-07-24 | Zhang Larry | Officer | A-Award | D | Employee Stock Option (Right to Buy) | 800,000 | 1.28 | 1.02M | 800,000 | — | ↗ |
| 2021-06-15 | Zhou Quan | Director | A-Award | A | Stock Option (Right to Buy) | 108,257 | 1.65 | 178.6K | 108,257 | — | ↗ |
| 2021-06-15 | Wu Yue Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 110,459 | 1.65 | 182.3K | 110,459 | — | ↗ |
| 2021-06-15 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Option (Right to Buy) | 110,459 | 1.65 | 182.3K | 110,459 | — | ↗ |
| 2021-06-15 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Option (Right to Buy) | 98 | 1.65 | 162.28 | 98,349 | — | ↗ |
| 2021-06-15 | Huang James | Director | A-Award | A | Stock Option (Right to Buy) | 113,028 | 1.65 | 186.5K | 113,028 | — | ↗ |
| 2021-06-15 | He Wei-Wu | Director / Officer / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 4,000,000 | 1.73 | 6.92M | 4,000,000 | — | ↗ |
| 2021-03-26 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 3,000,000 | 2.05 | 6.15M | 3,000,000 | — | ↗ |
| 2020-12-22 | He Wei-Wu | Director / Officer | G-Gift | D | Common Stock | 380,000 | 0.00 | — | 4,683,994 | — | ↗ |
| 2020-12-17 | Xu Weihao | Officer | P-Purchase | A | Common Stock | 2,279 | 2.63 | 6.0K | 10,000 | — | ↗ |
| 2020-12-16 | Xu Weihao | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 800,000 | 2.61 | 2.09M | 800,000 | — | ↗ |
| 2020-11-23 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 2.18 | 218.0K | 5,063,994 | — | ↗ |
| 2020-11-20 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 127,471 | 2.12 | 270.2K | 4,963,994 | — | ↗ |
| 2020-07-22 | Zhang Larry | Officer | P-Purchase | A | Common Stock | 20,153 | 1.90 | 38.3K | 20,153 | — | ↗ |
| 2020-07-22 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,952,426 | 1.90 | 5.61M | 4,836,523 | — | ↗ |
| 2020-06-16 | Zhou Quan | Director | A-Award | A | Stock Option (Right to Buy) | 67,429 | 2.63 | 177.3K | 67,429 | — | ↗ |
| 2020-06-16 | Wu Yue Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 68,800 | 2.63 | 180.9K | 68,800 | — | ↗ |
| 2020-06-16 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Option (Right to Buy) | 68,800 | 2.63 | 180.9K | 68,800 | — | ↗ |
| 2020-06-16 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Option (Right to Buy) | 61,257 | 2.63 | 161.1K | 61,257 | — | ↗ |
| 2020-06-16 | Huang James | Director | A-Award | A | Stock Option (Right to Buy) | 70,400 | 2.63 | 185.2K | 70,400 | — | ↗ |
| 2020-05-20 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 56,464 | 2.37 | 133.8K | 1,884,097 | — | ↗ |
| 2020-05-19 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 29,801 | 2.03 | 60.5K | 1,827,663 | — | ↗ |
| 2020-05-18 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 338,932 | 2.02 | 684.6K | 1,797,832 | — | ↗ |
| 2020-05-15 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 1.82 | 182.0K | 1,458,900 | — | ↗ |
| 2020-03-27 | He Wei-Wu | Director / Officer | P-Purchase | A | Common Stock | 6,880 | 2.08 | 14.3K | 1,358,900 | — | ↗ |
| 2020-03-26 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 328,095 | 2.09 | 685.7K | 1,352,020 | — | ↗ |
| 2020-03-25 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 196,398 | 1.94 | 381.0K | 1,023,925 | — | ↗ |
| 2020-03-19 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 234,488 | 1.57 | 368.1K | 6,332,347 | — | ↗ |
| 2020-03-18 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 501,322 | 1.52 | 762.0K | 6,097,859 | — | ↗ |
| 2020-03-17 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 264,192 | 1.50 | 396.3K | 5,596,537 | — | ↗ |
| 2019-12-30 | Wealth Strategy Holding Ltd | 10% Owner | X-InTheMoney | D | Warrant | 493,827 | 1.69 | 834.6K | 0 | — | ↗ |
| 2019-12-16 | He Wei-Wu | Director / Officer / 10% Owner | X-InTheMoney | A | Common Stock | 374,321 | 1.69 | 632.6K | 5,332,345 | — | ↗ |
| 2019-12-15 | Zukiwski Alexander A | Officer | A-Award | D | Employee Stock Option (Right to Buy) | 200,000 | 3.16 | 632.0K | 200,000 | — | ↗ |
| 2019-09-20 | Zhang Larry | Officer | A-Award | D | Employee Stock Option (Right to Buy) | 200,000 | 3.35 | 670.0K | 200,000 | — | ↗ |
| 2019-08-16 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 3.20 | 64.0K | 827,527 | — | ↗ |
| 2019-08-14 | He Wei-Wu | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 160,000 | 3.17 | 507.2K | 807,527 | — | ↗ |
| 2019-06-20 | Zhou Quan | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 56,731 | 3.13 | 177.6K | 56,731 | — | ↗ |
| 2019-06-20 | Wu Yue Alexander | Director | A-Award | A | Stock Option (Right to Buy) | 57,885 | 3.13 | 181.2K | 57,885 | — | ↗ |
| 2019-06-20 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Option (Right to Buy) | 57,885 | 3.13 | 181.2K | 57,885 | — | ↗ |
| 2019-06-20 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Option (Right to Buy) | 51,538 | 3.13 | 161.3K | 51,538 | — | ↗ |
| 2019-06-20 | Ren Ken Keyong | Director | A-Award | A | Stock Option (Right to Buy) | 51,538 | 3.13 | 161.3K | 51,538 | — | ↗ |
| 2019-06-20 | Huang James | Director | A-Award | A | Stock Option (Right to Buy) | 59,231 | 3.13 | 185.4K | 59,231 | — | ↗ |
| 2019-06-20 | He Wei-Wu | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 4,000,000 | 2.85 | 11.40M | 4,000,000 | — | ↗ |
| 2019-04-02 | SPECTRUM PHARMACEUTICALS INC | 10% Owner | J-Other | D | Common Stock | 1,500,000 | 3.38 | 5.07M | 5,397,413 | — | ↗ |
| 2019-03-23 | Wealth Strategy Holding Ltd | 10% Owner | — | D | Warrant | 559,701 | 7.19 | 4.02M | 0 | — | ↗ |
| 2019-03-23 | Li Dapeng | 10% Owner | — | D | Warrant (right to buy) | 167,910 | 7.19 | 1.21M | 0 | — | ↗ |
| 2019-01-29 | Ren Ken Keyong | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 75,000 | 0.88 | 66.0K | 75,000 | — | ↗ |
| 2019-01-29 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 75,000 | 0.88 | 66.0K | 75,000 | — | ↗ |
| 2019-01-14 | Hu Cynthia W. | Officer | M-Exempt | A | Common Stock | 15,000 | 1.76 | 26.4K | 32,785 | — | ↗ |
| 2018-12-19 | He Wei-Wu | Director / 10% Owner | G-Gift | D | Common Stock | 200,000 | 0.00 | — | 647,527 | — | ↗ |
| 2018-12-03 | Ren Ken Keyong | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 720,000 | 0.99 | 712.8K | 720,000 | — | ↗ |
| 2018-11-13 | SPARKLE BYTE LTD | 10% Owner | X-InTheMoney | A | Common Stock | 1,699,753 | 1.69 | 2.87M | 10,198,518 | — | ↗ |
| 2018-10-01 | Zhang Larry | Officer | — | D | Stock Options (Right to Buy) | 1,000,000 | 6.95 | 6.95M | 0 | — | ↗ |
| 2018-09-28 | Chi George | Officer | A-Award | A | Stock Options (Right to Buy) | 400,000 | 4.67 | 1.87M | 400,000 | — | ↗ |
| 2018-09-24 | Wealth Strategy Holding Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,594,061 | — | ↗ |
| 2018-09-17 | Wealth Strategy Holding Ltd | 10% Owner | — | D | Warrant | 370,370 | 3.69 | 1.37M | 0 | — | ↗ |
| 2018-09-11 | Li Dapeng | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 7,756,801 | — | ↗ |
| 2018-07-12 | CAPITELLI SARA B | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 35,000 | 1.99 | 69.5K | 0 | — | ↗ |
| 2018-06-29 | Zhou Quan | Director / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 50,000 | 8.23 | 411.5K | 50,000 | — | ↗ |
| 2018-06-29 | Wu Alex | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 8.23 | 288.1K | 35,000 | — | ↗ |
| 2018-06-29 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 8.23 | 288.1K | 35,000 | — | ↗ |
| 2018-06-29 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 8.23 | 288.1K | 35,000 | — | ↗ |
| 2018-06-29 | Huang James | Director | A-Award | A | Stock Options (Right to Buy) | 50,000 | 8.23 | 411.5K | 50,000 | — | ↗ |
| 2018-06-11 | He Wei-Wu | Director / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 1,000,000 | 3.22 | 3.22M | 1,000,000 | — | ↗ |
| 2018-04-17 | Wealth Strategy Holding Ltd | 10% Owner | — | D | Warrant | 666,666 | 3.75 | 2.50M | 0 | — | ↗ |
| 2018-04-17 | Li Dapeng | 10% Owner | — | D | Warrant (right to buy) | 616,375 | 3.75 | 2.31M | 0 | — | ↗ |
| 2018-04-12 | CAPITELLI SARA B | Officer | M-Exempt | A | Common Stock | 26,978 | 0.88 | 23.7K | 26,978 | — | ↗ |
| 2018-04-04 | Huang James | Director | J-Other | D | Common Stock | 416,666 | 0.00 | — | 0 | — | ↗ |
| 2018-03-21 | IDG-Accel China Growth Fund III L.P. | 10% Owner | P-Purchase | A | Common Stock | 2,882,098 | 3.19 | 9.19M | 9,126,375 | — | ↗ |
| 2018-03-19 | He Wei-Wu | Director / 10% Owner | A-Award | A | Warrants (Right to Buy) | 1,234,567 | 3.69 | 4.56M | 1,234,567 | — | ↗ |
| 2017-12-22 | SPECTRUM PHARMACEUTICALS INC | Director | P-Purchase | A | Common Stock | 907,356 | 0.01 | 9.1K | 6,897,413 | — | ↗ |
| 2017-10-13 | Li Dapeng | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,081,875 | — | ↗ |
| 2017-10-10 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 100,000 | 1.95 | 195.0K | 847,527 | — | ↗ |
| 2017-10-06 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 100,000 | 1.86 | 186.0K | 747,527 | — | ↗ |
| 2017-10-05 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 100,000 | 1.80 | 180.0K | 647,527 | — | ↗ |
| 2017-09-29 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 50,000 | 1.99 | 99.3K | 50,000 | — | ↗ |
| 2017-09-29 | CAPITELLI SARA B | Officer | A-Award | A | Stock Options (Right to Buy) | 20,000 | 1.99 | 39.7K | 20,000 | — | ↗ |
| 2017-09-19 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 34,002 | 1.78 | 60.5K | 547,527 | — | ↗ |
| 2017-09-18 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 173,500 | 1.75 | 303.6K | 513,525 | — | ↗ |
| 2017-09-15 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 127,702 | 1.49 | 190.3K | 340,025 | — | ↗ |
| 2017-09-14 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 187,625 | 1.22 | 228.9K | 212,323 | — | ↗ |
| 2017-07-10 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 50,000 | 1.01 | 50.3K | 50,000 | — | ↗ |
| 2017-06-08 | Zhou Quan | Director / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 50,000 | 1.01 | 50.3K | 50,000 | — | ↗ |
| 2017-06-08 | Wu Alex | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 1.01 | 35.2K | 35,000 | — | ↗ |
| 2017-06-08 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 1.01 | 35.2K | 35,000 | — | ↗ |
| 2017-06-08 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 1.01 | 35.2K | 35,000 | — | ↗ |
| 2017-06-08 | Huang James | Director | A-Award | A | Stock Options (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2017-06-08 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 100,000 | 1.01 | 100.6K | 100,000 | — | ↗ |
| 2017-06-08 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 100,000 | 1.01 | 100.6K | 100,000 | — | ↗ |
| 2017-06-08 | CAPITELLI SARA B | Officer | A-Award | A | Stock Options (Right to Buy) | 50,000 | 1.01 | 50.3K | 50,000 | — | ↗ |
| 2017-04-03 | Zukiwski Alexander A | Officer | A-Award | A | Stock Options (Right to Buy) | 300,000 | 1.34 | 402.0K | 300,000 | — | ↗ |
| 2017-01-23 | Wealth Strategy Holding Ltd | 10% Owner | — | D | Warrant | 493,827 | 1.69 | 834.6K | 0 | — | ↗ |
| 2017-01-02 | Li Dapeng | 10% Owner | — | I | Warrant (right to buy) | 246,913 | 1.69 | 417.3K | 0 | — | ↗ |
| 2016-10-28 | SPECTRUM PHARMACEUTICALS INC | 10% Owner | P-Purchase | A | Common Stock | 294,815 | 0.01 | 2.9K | 5,990,057 | — | ↗ |
| 2016-10-24 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 202,247 | 1.40 | 283.1K | 202,247 | — | ↗ |
| 2016-10-03 | Ren Ken Keyong | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 308,571 | 1.11 | 342.5K | 308,571 | — | ↗ |
| 2016-10-03 | He Wei-Wu | Director | A-Award | A | Warrants | 374,321 | 1.69 | 632.6K | 374,321 | — | ↗ |
| 2016-07-20 | SPECTRUM PHARMACEUTICALS INC | 10% Owner | P-Purchase | A | Common Stock | 98,271 | 0.01 | 982.71 | 4,921,452 | — | ↗ |
| 2016-07-14 | SPECTRUM PHARMACEUTICALS INC | 10% Owner | P-Purchase | A | Common Stock | 585,790 | 0.01 | 5.9K | 4,823,181 | — | ↗ |
| 2016-07-05 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 84,507 | 1.10 | 93.0K | 84,507 | — | ↗ |
| 2016-06-24 | SPARKLE BYTE LTD | 10% Owner | P-Purchase | A | Warrant | 750,771 | 1.69 | 1.27M | 1,699,753 | — | ↗ |
| 2016-06-24 | Ren Ken Keyong | Director / Officer | A-Award | A | Stock Options(Right to Buy) | 86,486 | 1.15 | 99.5K | 86,486 | — | ↗ |
| 2016-06-24 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 27,027 | 1.15 | 31.1K | 27,027 | — | ↗ |
| 2016-06-24 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 369,805 | 1.15 | 425.3K | 369,805 | — | ↗ |
| 2016-06-02 | Zhou Quan | Director / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 50,000 | 1.26 | 63.0K | 50,000 | — | ↗ |
| 2016-06-02 | Ren Ken Keyong | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 280,701 | 0.86 | 241.4K | 280,701 | — | ↗ |
| 2016-06-02 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 87,719 | 0.86 | 75.4K | 87,719 | — | ↗ |
| 2016-06-02 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 712,112 | 0.86 | 612.5K | 712,112 | — | ↗ |
| 2016-04-14 | SPARKLE BYTE LTD | 10% Owner | — | D | Warrant | 948,982 | 1.69 | 1.60M | 0 | — | ↗ |
| 2016-03-02 | Wu Alex | Director | A-Award | A | Options (Right to Buy) | 35,000 | 0.88 | 30.8K | 35,000 | — | ↗ |
| 2016-03-02 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 0.88 | 30.8K | 35,000 | — | ↗ |
| 2016-03-02 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 0.88 | 30.8K | 35,000 | — | ↗ |
| 2016-03-02 | Ren Ken Keyong | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 125,000 | 0.88 | 110.0K | 125,000 | — | ↗ |
| 2016-03-02 | Mak Tak W. | Director | A-Award | A | Stock Options (Right to Buy) | 35,000 | 0.88 | 30.8K | 35,000 | — | ↗ |
| 2016-03-02 | Huang James | Director | A-Award | A | Options (Right to Buy) | 75,000 | 0.88 | 66.0K | 75,000 | — | ↗ |
| 2016-03-02 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 95,000 | 0.00 | — | 95,000 | — | ↗ |
| 2016-03-02 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 100,000 | 0.88 | 88.0K | 100,000 | — | ↗ |
| 2016-03-02 | CAPITELLI SARA B | Officer | A-Award | A | Stock Options (Right to Buy) | 35,000 | 0.88 | 30.8K | 35,000 | — | ↗ |
| 2016-02-22 | SPECTRUM PHARMACEUTICALS INC | 10% Owner | P-Purchase | A | Common Stock | 680,113 | 0.01 | 6.8K | 2,856,868 | — | ↗ |
| 2016-01-19 | Ren Ken Keyong | Director / Officer | P-Purchase | A | Common Stock | 1,100 | 0.74 | 814.00 | 8,637 | — | ↗ |
| 2016-01-19 | Ren Ken | Director / Officer | P-Purchase | A | Common Stock | 6,063 | 0.72 | 4.4K | 14,700 | — | ↗ |
| 2016-01-19 | Hu Cynthia W. | Officer | P-Purchase | A | Common Stock | 400 | 0.75 | 299.12 | 1,385 | — | ↗ |
| 2016-01-14 | SPARKLE BYTE LTD | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,744,910 | — | ↗ |
| 2015-04-06 | Wu Alex | Director | A-Award | A | Options(Right to Buy) | 35,000 | 1.41 | 49.4K | 35,000 | — | ↗ |
| 2015-04-06 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Options(Right to Buy) | 35,000 | 1.41 | 49.4K | 35,000 | — | ↗ |
| 2015-04-06 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Stock Options(Right to Buy) | 35,000 | 1.41 | 49.4K | 35,000 | — | ↗ |
| 2015-04-06 | Ren Ken Keyong | Director / Officer | A-Award | A | Stock Options(Right to Buy) | 225,000 | 1.41 | 317.3K | 225,000 | — | ↗ |
| 2015-04-06 | Mak Tak W. | Director | A-Award | A | Stock Options(Right to Buy) | 35,000 | 1.41 | 49.4K | 35,000 | — | ↗ |
| 2015-04-06 | Huang James | Director | A-Award | A | Options(Right to Buy) | 75,000 | 1.41 | 105.8K | 75,000 | — | ↗ |
| 2015-04-06 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 175,000 | 1.41 | 246.8K | 175,000 | — | ↗ |
| 2015-04-06 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 100,000 | 1.41 | 141.0K | 100,000 | — | ↗ |
| 2015-04-06 | CAPITELLI SARA B | Officer | A-Award | A | Stock Options (Right to Buy) | 65,000 | 1.41 | 91.7K | 65,000 | — | ↗ |
| 2014-09-22 | SHROTRIYA RAJESH C MD | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-09-17 | SPECTRUM PHARMACEUTICALS INC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,176,755 | — | ↗ |
| 2014-09-17 | Huang James | Director | A-Award | A | Options(Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2014-06-02 | Salisbury Franklin Cary jr | Director | A-Award | A | Stock Options (Right to Buy) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2014-04-03 | Ren Ken Keyong | Officer | A-Award | A | Stock Options(Right to Buy) | 100,000 | 1.84 | 184.0K | 100,000 | — | ↗ |
| 2014-04-03 | Mak Tak W. | Director | A-Award | A | Stock Options (Right to Buy) | 25,000 | 1.84 | 46.0K | 25,000 | — | ↗ |
| 2014-04-03 | Huang James | Director | A-Award | A | Options (Right to Buy) | 75,000 | 1.84 | 138.0K | 75,000 | — | ↗ |
| 2014-04-03 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 100,000 | 1.84 | 184.0K | 100,000 | — | ↗ |
| 2014-04-03 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 100,000 | 1.84 | 184.0K | 100,000 | — | ↗ |
| 2014-04-03 | CAPITELLI SARA B | Officer | A-Award | A | Stock Options (Right to Buy) | 55,000 | 1.84 | 101.2K | 55,000 | — | ↗ |
| 2013-09-04 | Huang James | Director | — | I | Warrants | 208,333 | 2.91 | 606.2K | 0 | — | ↗ |
| 2013-05-30 | Wu Alex | Director | A-Award | A | Stock Options (Right to Buy) | 50,000 | 1.79 | 89.5K | 50,000 | — | ↗ |
| 2013-05-30 | Ren Ken Keyong | Officer | A-Award | A | Stock Options (Right to Buy) | 1,000,000 | 1.79 | 1.79M | 1,000,000 | — | ↗ |
| 2013-05-30 | Mak Tak W. | Director | A-Award | A | Stock Options (Right to Buy) | 37,500 | 1.79 | 67.1K | 37,500 | — | ↗ |
| 2013-05-30 | Huang James | Director | A-Award | A | Stock Options (Right to Buy) | 50,000 | 1.79 | 89.5K | 50,000 | — | ↗ |
| 2013-05-30 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 350,000 | 1.79 | 626.5K | 350,000 | — | ↗ |
| 2013-05-30 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 125,000 | 1.79 | 223.8K | 125,000 | — | ↗ |
| 2013-05-30 | HUNTER CEVERA JENNIE | Director | A-Award | A | Stock Options (Right to Buy) | 37,500 | 1.79 | 67.1K | 37,500 | — | ↗ |
| 2013-05-30 | CAPITELLI SARA B | Officer | A-Award | A | Stock Options (Right to Buy) | 125,000 | 1.79 | 223.8K | 125,000 | — | ↗ |
| 2013-05-30 | BUSH DWIGHT L | Director | A-Award | A | Stock Options (Right to Buy) | 37,500 | 1.79 | 67.1K | 37,500 | — | ↗ |
| 2013-04-04 | Wu Alex | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-04-04 | Huang James | Director | — | I | Common Stock | 0 | 0.00 | — | 416,666 | — | ↗ |
| 2013-03-07 | IDG-Accel China Growth Fund III L.P. | 10% Owner | P-Purchase | A | Warrant | 34,479 | 2.91 | 100.3K | 92,044 | — | ↗ |
| 2012-08-15 | Hu Cynthia W. | Officer | A-Award | A | Stock Options (Right to Buy) | 75,000 | 1.99 | 148.9K | 75,000 | — | ↗ |
| 2012-08-15 | CAPITELLI SARA B | Officer | A-Award | A | Stock Options (Right to Buy) | 20,000 | 1.99 | 39.7K | 20,000 | — | ↗ |
| 2012-07-29 | IDG-Accel China Growth Fund III L.P. | 10% Owner | — | I | Warrant | 57,565 | 1.40 | 80.6K | 0 | — | ↗ |
| 2012-05-01 | Hu Cynthia W. | Officer | P-Purchase | A | Common Stock | 74,982 | 1.15 | 86.2K | 74,982 | — | ↗ |
| 2012-05-01 | He Wei-Wu | Director | P-Purchase | A | Common Stock | 441,072 | 1.15 | 507.2K | 441,072 | — | ↗ |
| 2012-04-30 | IDG-Accel China Growth Fund III L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,118,730 | — | ↗ |
| 2012-04-02 | Ren Ken Keyong | Officer | A-Award | A | Stock Options (Right to Buy) | 150,000 | 2.16 | 324.0K | 150,000 | — | ↗ |
| 2012-03-12 | RANDALL MARK C M | Director | A-Award | A | Stock Options (Right to Buy) | 50,000 | 2.30 | 115.0K | 50,000 | — | ↗ |
| 2012-03-12 | Mak Tak W. | Director | A-Award | A | Stock Options (Right to Buy) | 125,000 | 2.30 | 287.5K | 125,000 | — | ↗ |
| 2012-03-12 | BUSH DWIGHT L | Director | A-Award | A | Stock Options (Right to Buy) | 100,000 | 2.30 | 230.0K | 100,000 | — | ↗ |
| 2012-03-01 | He Wei-Wu | Director | A-Award | A | Stock Options (Right to Buy) | 250,000 | 1.95 | 487.5K | 250,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.8K
Shares Outstanding
20.56M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Wei-Wu He, Ph.D. Chief Executive Officer | 322.4K | — | — | 9.10M | — | 243.0K | 9.67M | 94.15% | ↗ |
| 2 | 2021 | Wei (Larry) Zhang President | 554.4K | 232.4K | — | 1.42M | — | 344.4K | 2.56M | 55.73% | ↗ |
| 3 | 2021 | Alexander Zukiwski, MD EVP & Chief Medical Officer | 451.4K | 25.0K | — | 666.6K | — | 38.3K | 1.18M | 56.42% | ↗ |
| 4 | 2020 | Weihao Xu Former Chief Financial Officer | 14.6K | — | — | 1.44M | — | — | 1.45M | 99.00% | ↗ |
| 5 | 2020 | Wei-Wu He, Ph.D. Chief Executive Officer | 577.7K | — | — | — | — | 241.8K | 819.5K | 0.00% | ↗ |
| 6 | 2020 | Wei (Larry) Zhang President | 437.1K | — | — | — | — | 278.7K | 715.8K | 0.00% | ↗ |
| 7 | 2020 | Alexander Zukiwski, MD Chief Medical Officer | 414.5K | — | — | — | — | 28.3K | 442.8K | 0.00% | ↗ |
| 8 | 2020 | Alexander Zukiwski, MD EVP & Chief Medical Officer | 414.5K | — | — | — | — | 28.3K | 442.8K | 0.00% | ↗ |
| 9 | 2019 | Wei-Wu He, Ph.D. Chief Executive Officer | 423.8K | — | — | 8.60M | — | 241.6K | 9.27M | 92.82% | ↗ |
| 10 | 2019 | Wei (Larry) Zhang President | 339.2K | — | — | 450.0K | — | 166.9K | 985.2K | 45.68% | ↗ |
| 11 | 2019 | Alexander Zukiwski, MD Chief Medical Officer | 407.6K | 100.0K | — | 426.0K | — | 27.8K | 961.4K | 44.31% | ↗ |
| 12 | 2019 | Ken K. Ren, Ph.D. Former CEO and Former Director | 108.6K | — | — | — | — | 301.6K | 410.2K | 0.00% | ↗ |
| 13 | 2018 | Wei (Larry) Zhang President, CASI China | 98.6K | — | — | 4.85M | — | 49.3K | 5.00M | 97.04% | ↗ |
| 14 | 2018 | Wei (Larry) Zhang President | 98.6K | — | — | 4.85M | — | 49.3K | 5.00M | 97.04% | ↗ |
| 15 | 2018 | George Chi Chief Financial Officer | 76.3K | — | — | 1.31M | — | 4.9K | 1.39M | 94.18% | ↗ |
| 16 | 2018 | Ken K. Ren, Ph.D. Former CEO and Former Director | 428.0K | 120.0K | — | 538.4K | — | 150.8K | 1.24M | 43.52% | ↗ |
| 17 | 2018 | Ken K. Ren, PhD Chief Executive Officer | 428.0K | 120.0K | — | 538.4K | — | 150.8K | 1.24M | 43.52% | ↗ |
| 18 | 2017 | Ken K. Ren, PhD Chief Executive Officer | 389.4K | 370.0K | — | — | — | 29.0K | 788.4K | 0.00% | ↗ |
| 19 | 2017 | Alexander A. Zukiwski, MD Chief Medical Officer | 300.0K | 20.0K | — | 279.0K | — | 13.0K | 612.0K | 45.59% | ↗ |
| 20 | 2017 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 329.2K | — | — | 98.5K | — | 39.4K | 467.1K | 21.09% | ↗ |
| 21 | 2016 | Ken K. Ren, PhD Chief Executive Officer | 300.0K | — | — | 612.9K | — | 8.0K | 920.9K | 66.56% | ↗ |
| 22 | 2016 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 300.0K | — | — | 158.7K | — | 17.6K | 476.3K | 33.33% | ↗ |
| 23 | 2016 | Sara B. Capitelli, CPA Vice President, Finance & | 185.1K | — | — | 21.7K | — | 15.4K | 222.2K | 9.77% | ↗ |
| 24 | 2015 | Ken K. Ren, PhD Chief Executive Officer | 300.0K | — | — | 229.5K | — | 7.3K | 536.8K | 42.76% | ↗ |
| 25 | 2015 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 300.0K | — | — | 178.5K | — | 7.8K | 486.3K | 36.71% | ↗ |
| 26 | 2015 | Sara B. Capitelli, CPA Vice President, Finance & | 175.1K | — | — | 66.3K | — | 5.3K | 246.7K | 26.88% | ↗ |
| 27 | 2014 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 300.0K | — | — | 414.1K | — | 7.5K | 721.6K | 57.39% | ↗ |
| 28 | 2014 | Ken K. Ren, PhD Chief Executive Officer | 300.0K | — | — | 364.5K | — | 7.0K | 671.5K | 54.28% | ↗ |
| 29 | 2014 | Sara B. Capitelli, CPA Vice President, Finance & | 175.1K | — | — | 112.5K | — | 5.3K | 292.8K | 38.40% | ↗ |
| 30 | 2013 | Ken K. Ren, PhD Chief Executive Officer | 285.2K | — | — | 1.43M | — | 5.4K | 1.72M | 83.11% | ↗ |
| 31 | 2013 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 300.0K | — | — | 500.5K | — | 6.8K | 807.3K | 62.00% | ↗ |
| 32 | 2013 | Sara B. Capitelli, CPA Vice President, Finance & | 175.1K | — | — | 178.8K | — | 5.3K | 359.1K | 49.78% | ↗ |
| 33 | 2012 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 300.0K | — | — | 252.8K | — | 7.5K | 635.3K | 39.79% | ↗ |
| 34 | 2012 | Ken K. Ren, PhD Chief Executive Officer | 177.1K | — | — | 253.5K | — | 2.2K | 432.8K | 58.58% | ↗ |
| 35 | 2012 | Carolyn F. Sidor, MD Former Vice President & Chief Medical Officer | 165.4K | — | — | — | — | 153.9K | 319.3K | 0.00% | ↗ |
| 36 | 2012 | Sara B. Capitelli, CPA Vice President, Finance & | 174.2K | — | — | 55.0K | — | 5.2K | 234.4K | 23.44% | ↗ |
| 37 | 2011 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 300.0K | — | — | 139.5K | — | 6.4K | 445.9K | 31.28% | ↗ |
| 38 | 2011 | Carolyn F. Sidor, MD Former Vice President & Chief Medical Officer | 300.0K | — | — | 139.5K | — | 4.5K | 444.0K | 31.42% | ↗ |
| 39 | 2011 | Carolyn F. Sidor, MD Vice President & Chief Medical Officer | 300.0K | — | — | 139.5K | — | 4.5K | 444.0K | 31.42% | ↗ |
| 40 | 2011 | Sara B. Capitelli, CPA Vice President, Finance & | 159.1K | 5.0K | — | 47.1K | — | 4.3K | 215.5K | 21.86% | ↗ |
| 41 | 2010 | Carolyn F. Sidor, MD Vice President & Chief Medical Officer | 300.0K | 50.0K | — | — | — | 4.5K | 354.5K | 0.00% | ↗ |
| 42 | 2010 | Carolyn F. Sidor, MD Vice President & CMO | 300.0K | 50.0K | — | — | — | 4.5K | 354.5K | 0.00% | ↗ |
| 43 | 2010 | Cynthia W. Hu, JD Chief Operating Officer, General Counsel & Secretary | 300.0K | 50.0K | — | — | — | 1.5K | 351.5K | 0.00% | ↗ |
| 44 | 2010 | Cynthia W. Hu, JD COO & General Counsel | 300.0K | 50.0K | — | — | — | 1.5K | 351.5K | 0.00% | ↗ |
| 45 | 2010 | Kathy Wehmeir-Davis Former Principal Accounting Officer | 200.0K | — | — | — | — | 53.4K | 253.4K | 0.00% | ↗ |
| 46 | 2010 | Mark R. Bray, PhD Vice President, Research | 200.0K | 12.5K | — | — | — | — | 212.5K | 0.00% | ↗ |
| 47 | 2009 | Carolyn F. Sidor, MD Vice President and Chief Medical Officer | 300.0K | — | — | 32.0K | — | 4.5K | 336.5K | 9.51% | ↗ |
| 48 | 2009 | Carolyn F. Sidor, MD Vice President & CMO | 300.0K | — | — | 32.0K | — | 4.5K | 336.5K | 9.51% | ↗ |
| 49 | 2009 | Cynthia W. Hu, JD COO & General Counsel | 300.0K | — | — | 26.4K | — | 1.5K | 327.9K | 8.05% | ↗ |
| 50 | 2009 | Cynthia W. Hu, JD Chief Operating Officer & General Counsel | 300.0K | — | — | 26.4K | — | 1.5K | 327.9K | 8.05% | ↗ |
| 51 | 2009 | Kathy R. Wehmeir-Davis Principal Accounting Officer | 200.0K | — | — | 22.4K | — | 52.4K | 274.8K | 8.15% | ↗ |
| 52 | 2009 | Kathy Wehmeir-Davis Former Principal Accounting Officer | 200.0K | — | — | 22.4K | — | 52.4K | 274.8K | 8.15% | ↗ |
| 53 | 2009 | Mark R. Bray, PhD Vice President, Research | 200.0K | — | — | 22.4K | — | — | 222.4K | 10.07% | ↗ |
| 54 | 2008 | James S. Burns Former President & CEO | 430.0K | — | — | 310.8K | — | 6.8K | 747.7K | 41.58% | ↗ |
| 55 | 2008 | Kenneth W. Bair, PhD Former Sr. VP, R&D | 320.0K | — | — | 79.0K | — | 6.3K | 405.2K | 19.49% | ↗ |
| 56 | 2008 | Carolyn F. Sidor, MD Vice President and CMO | 300.0K | — | — | 41.5K | — | 4.8K | 346.3K | 11.98% | ↗ |
| 57 | 2008 | Dane R. Saglio Former CFO | 270.0K | — | — | 64.9K | — | 6.4K | 341.3K | 19.01% | ↗ |
| 58 | 2008 | Carolyn F. Sidor, MD Vice President and Chief Medical Officer | 300.0K | — | — | — | — | 4.8K | 304.8K | 0.00% | ↗ |
| 59 | 2008 | Carolyn F. Sidor, MD Vice President & CMO | 300.0K | — | — | — | — | 4.8K | 304.8K | 0.00% | ↗ |
| 60 | 2008 | Cynthia W. Hu, JD COO & General Counsel | 260.0K | — | — | — | — | 3.5K | 263.5K | 0.00% | ↗ |
| 61 | 2008 | Cynthia W. Hu, JD Chief Operating Officer & General Counsel | 260.0K | — | — | — | — | 3.5K | 263.5K | 0.00% | ↗ |
| 62 | 2008 | Kathy Wehmeir-Davis Former Principal Accounting Officer | 100.0K | — | — | — | — | 47.4K | 147.4K | 0.00% | ↗ |
| 63 | 2008 | Kathy R. Wehmeir-Davis Principal Accounting Officer | 100.0K | — | — | — | — | 47.4K | 147.4K | 0.00% | ↗ |
| 64 | 2007 | James S. Burns Former President & CEO | 414.0K | — | — | 237.3K | 165.0K | — | 816.3K | 29.07% | ↗ |
| 65 | 2007 | James S. Burns President and Chief Executive Officer | 414.0K | — | — | 237.3K | 165.0K | — | 816.3K | 29.07% | ↗ |
| 66 | 2007 | Carolyn F. Sidor, MD Vice President and CMO | 280.0K | — | — | 67.7K | 70.0K | 6.6K | 424.3K | 15.95% | ↗ |
| 67 | 2007 | Dane R. Saglio Former CFO | 240.0K | — | — | 50.5K | 60.0K | 7.0K | 357.5K | 14.12% | ↗ |
| 68 | 2007 | Dane R. Saglio Chief Financial Officer | 240.0K | — | — | 50.5K | 60.0K | 7.0K | 357.5K | 14.12% | ↗ |
| 69 | 2007 | Carolyn F. Sidor, MD Vice President and Chief Medical Officer | 280.0K | — | — | — | 70.0K | 6.6K | 356.6K | 0.00% | ↗ |
| 70 | 2007 | Cynthia Wong Hu, JD Vice President, General Counsel & Secretary | 230.0K | — | — | 52.5K | 58.0K | 3.7K | 344.3K | 15.26% | ↗ |
| 71 | 2007 | Cynthia W. Hu, JD COO & General Counsel | 230.0K | — | — | 52.5K | 58.0K | 3.7K | 344.3K | 15.26% | ↗ |
| 72 | 2007 | Cynthia W. Hu, JD Chief Operating Officer & General Counsel | 230.0K | — | — | — | 58.0K | 3.7K | 291.7K | 0.00% | ↗ |
| 73 | 2007 | Marc G. Corrado Former Vice President, Corporate Development | 228.0K | — | — | 50.1K | — | 5.6K | 283.7K | 17.65% | ↗ |
| 74 | 2007 | Kenneth W. Bair, PhD Former Sr. VP, R&D | 53.0K | — | — | 98.7K | 15.0K | 100.0K | 266.7K | 37.01% | ↗ |
| 75 | 2007 | Kenneth W. Bair, PhD Senior Vice President, Research & Development | 53.0K | — | — | 98.7K | 15.0K | 100.0K | 266.7K | 37.01% | ↗ |
| 76 | 2006 | James S. Burns , President and Chief Executive Officer | 400.0K | — | — | 283.3K | 180.0K | — | 863.3K | 32.82% | ↗ |
| 77 | 2006 | James S. Burns Former President & CEO | 400.0K | — | — | 283.3K | 180.0K | — | 863.3K | 32.82% | ↗ |
| 78 | 2006 | James S. Burns President and Chief Executive Officer | 400.0K | — | — | 283.3K | 180.0K | — | 863.3K | 32.82% | ↗ |
| 79 | 2006 | Carolyn F. Sidor, MD Vice President and CMO | 260.0K | — | — | 108.8K | 100.0K | 6.3K | 475.1K | 22.91% | ↗ |
| 80 | 2006 | Carolyn F. Sidor, MD Vice President and Chief Medical Officer | 260.0K | — | — | 108.8K | 100.0K | 6.3K | 475.1K | 22.91% | ↗ |
| 81 | 2006 | Carolyn F. Sidor, M.D., Vice President and Chief Medical Officer | 260.0K | — | — | 108.8K | 100.0K | 6.3K | 475.1K | 22.91% | ↗ |
| 82 | 2006 | Dane R. Saglio Chief Financial Officer | 232.0K | — | — | 87.9K | 58.0K | 6.6K | 384.5K | 22.86% | ↗ |
| 83 | 2006 | Dane R. Saglio Former CFO | 232.0K | — | — | 87.9K | 58.0K | 6.6K | 384.5K | 22.86% | ↗ |
| 84 | 2006 | Dane R. Saglio, Chief Financial Officer | 232.0K | — | — | 87.9K | 58.0K | 6.6K | 384.5K | 22.86% | ↗ |
| 85 | 2006 | Marc G. Corrado Former Vice President, Corporate Development | 220.0K | — | — | 103.2K | 55.0K | 5.6K | 383.8K | 26.90% | ↗ |
| 86 | 2006 | Marc G. Corrado Vice President, Corporate Development | 220.0K | — | — | 103.2K | 55.0K | 5.6K | 383.8K | 26.90% | ↗ |
| 87 | 2006 | Cynthia Wong Hu Vice President, General Counsel & Secretary | 126.0K | — | — | 64.0K | 30.0K | — | 220.0K | 29.08% | ↗ |
| 88 | 2006 | Cynthia W. Hu, JD COO & General Counsel | 126.0K | — | — | 64.0K | 30.0K | — | 220.0K | 29.08% | ↗ |
| 89 | 2006 | Cynthia Wong Hu, JD Vice President, General Counsel & Secretary | 126.0K | — | — | 64.0K | 30.0K | — | 220.0K | 29.08% | ↗ |
| 90 | 2005 | James S. Burns President and Chief Executive Officer | 372.0K | 160.0K | — | — | — | 10.6K | 542.6K | 0.00% | ↗ |
| 91 | 2005 | Carolyn F. Sidor, M.D. Vice President and Chief Medical Officer | 240.0K | 65.0K | — | 40.0K | — | 10.3K | 355.3K | 11.26% | ↗ |
| 92 | 2005 | Dane R. Saglio Chief Financial Officer | 220.0K | 55.0K | — | 40.0K | — | 13.5K | 328.5K | 12.18% | ↗ |
| 93 | 2005 | Marc G. Corrado, J.D. Vice President, Corporate Development | 153.0K | 40.4K | — | 25.0K | — | 47.5K | 265.9K | 9.40% | ↗ |
| 94 | 2005 | James D. Johnson, Ph.D., J.D. Senior Vice President and General Counsel | 10.8K | — | — | — | — | 40.00 | 10.8K | 0.00% | ↗ |
| 95 | 2004 | James S. Burns President and Chief Executive Officer | 195.0K | 80.0K | — | 600.0K | — | 4.1K | 879.1K | 68.25% | ↗ |
| 96 | 2004 | Carolyn F. Sidor, M.D. Corporate Vice President and Chief Medical Officer | 234.5K | 50.0K | — | 100.0K | — | 1.4K | 385.9K | 25.92% | ↗ |
| 97 | 2004 | Carolyn F. Sidor, M.D. Vice President and Chief Medical Officer | 234.5K | 50.0K | — | 100.0K | — | 1.4K | 385.9K | 25.92% | ↗ |
| 98 | 2004 | Neil J. Campbell President and Chief Operating Officer | 137.5K | — | — | 25.0K | — | 177.8K | 340.3K | 7.35% | ↗ |
| 99 | 2004 | Dane R. Saglio Chief Financial Officer | 200.0K | 50.0K | — | 75.0K | — | 12.7K | 337.7K | 22.21% | ↗ |
| 100 | 2004 | Udo Klein, Ph.D. Vice President Research & Development | 183.8K | — | — | — | — | 9.6K | 193.3K | 0.00% | ↗ |
| 101 | 2004 | James D. Johnson, Ph.D., J.D. Senior Vice President and General Counsel | 10.8K | — | — | — | — | 40.00 | 10.8K | 0.00% | ↗ |
| 102 | 2003 | Neil J. Campbell President and Chief Operating Officer | 309.4K | 85.0K | — | 50.0K | — | 142.2K | 586.6K | 8.52% | ↗ |
| 103 | 2003 | Dane R. Saglio Chief Financial Officer | 190.2K | 50.0K | — | 75.0K | — | 9.7K | 324.9K | 23.08% | ↗ |
| 104 | 2003 | Carolyn F. Sidor, M.D. Vice President and Chief Medical Officer | 226.6K | 22.6K | — | 50.0K | — | 288.00 | 299.5K | 16.70% | ↗ |
| 105 | 2003 | Carolyn F. Sidor, M.D. Corporate Vice President and Chief Medical Officer | 226.6K | 22.6K | — | 50.0K | — | 288.00 | 299.5K | 16.70% | ↗ |
| 106 | 2003 | Udo Klein Vice President Research & Development | 50.6K | — | — | 100.0K | — | 897.00 | 151.5K | 66.02% | ↗ |
| 107 | 2003 | Udo Klein, Ph.D. Vice President Research & Development | 50.6K | — | — | 100.0K | — | 897.00 | 151.5K | 66.02% | ↗ |
| 108 | 2003 | James D. Johnson, Ph.D., J.D. Senior Vice President and General Counsel | 10.8K | — | — | 40.0K | — | — | 50.8K | 78.74% | ↗ |
| 109 | 2002 | John W. Holaday, Ph.D. Chairman and Chief Executive Officer (Chairman until January 31, 2003 and CEO until November 5, 2002) | 398.8K | — | — | 280.0K | — | 22.3K | 701.2K | 39.93% | ↗ |
| 110 | 2002 | Neil J. Campbell President and Chief Operating Officer | 251.8K | — | — | 175.0K | — | 9.8K | 436.5K | 40.09% | ↗ |
| 111 | 2002 | Edward Gubish President and Chief Operating Officer (until October 16, 2002) | 257.2K | — | — | 40.0K | — | 80.5K | 377.7K | 10.59% | ↗ |
| 112 | 2002 | James D. Johnson, Ph.D., J.D. Senior Vice President and General Counsel | 209.4K | — | — | 100.0K | — | 666.00 | 310.0K | 32.25% | ↗ |
| 113 | 2002 | Carolyn F. Sidor, M.D. Corporate Vice President and Chief Medical Officer | 226.6K | — | — | 30.0K | — | 3.7K | 260.3K | 11.53% | ↗ |
| 114 | 2002 | Dane R. Saglio Chief Financial Officer | 122.8K | 50.0K | — | 35.0K | — | 9.8K | 217.6K | 16.08% | ↗ |
| 115 | 2001 | John W. Holaday, Ph.D. Chairman and Chief Executive Officer (Chairman until January 31, 2003 and CEO until November 5, 2002) | 395.0K | — | — | 250.0K | — | 22.4K | 667.4K | 37.46% | ↗ |
| 116 | 2001 | Edward Gubish President and Chief Operating Officer (until October 16, 2002) | 295.0K | — | — | 222.0K | — | 9.9K | 526.9K | 42.13% | ↗ |
| 117 | 2001 | James D. Johnson, Ph.D., J.D. Senior Vice President and General Counsel | 183.3K | — | — | 195.0K | — | 683.00 | 379.0K | 51.45% | ↗ |
| 118 | 2001 | Neil J. Campbell President and Chief Operating Officer | 159.4K | — | — | 205.0K | — | 5.8K | 370.1K | 55.38% | ↗ |
| 119 | 2001 | Dane R. Saglio Chief Financial Officer | 106.0K | 15.0K | — | 14.2K | — | 9.9K | 145.0K | 9.79% | ↗ |
| 120 | 2000 | John W. Holaday, Ph.D. Chairman and Chief Executive Officer (Chairman until January 31, 2003 and CEO until November 5, 2002) | 380.0K | 150.0K | — | 150.0K | — | 21.3K | 701.3K | 21.39% | ↗ |
| 121 | 2000 | Edward Gubish President and Chief Operating Officer (until October 16, 2002) | 250.0K | 125.0K | — | 115.0K | — | 8.7K | 498.7K | 23.06% | ↗ |
| 122 | 2000 | Dane R. Saglio Chief Financial Officer | 87.0K | 9.5K | — | 11.5K | — | 5.1K | 113.2K | 10.16% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wei Zhang | Senior Vice President | 1M | — |
| Alexander A. Zukiwski | Executive Vice President & Chief Medical Officer | 514.8K | — |
| David A. Cory | Chief Executive Officer & Director | — | male |
| Hai Huang | Chief Commercial Officer & GM | — | male |
| Ingrid C. Choong | Head of Corporate Development | — | — |
| James E. Goldschmidt | Chief Business Officer | — | — |
| Junping Chen | Senior VP of Medical of US & Chief Medical Officer of China | — | — |
| Kun Qian | Vice President & Global Controller | — | female |
| Wei Gao | General Counsel | — | female |
| Wei-Wu He | Executive Chairman of the Board & Principal Executive Officer | — | — |
| Chunhua Wang | Chief Operating Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CASIF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
